Podcasts

More Episodes

The Business Side of Drug Discovery

Today’s episode on the topic of The Business Side of Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Building the foundations for post COVID-19 R&D, Opportunity Knocks: Why compound screening libraries are worth the investment, and How to achieve data driven R&D at speed These articles were written by […]

Listen now

Innovation and Opportunity in Drug Discovery

Today’s episode on the topic of Innovation and Opportunity in Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Japanese drug development: Where is the innovation, Where are the opportunities in global drug discovery, and New for Old: The value behind drug repurposing. These articles were written by Lu […]

Listen now

2030 Life Sciences and Health in the Digital Age (Part 2)

The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in 2030, in particular how the increasing adoption and sophistication of technology will affect companies and patients alike. This article is the second part of a two-part series based on […]

Listen now

2030 Life Sciences and Health in the Digital Age (Part 1)

This article is the first in a two-part series based on The Pistoia Alliance report. Written in retrospect from the world as it is in 2030, it looks at how healthcare has changed in the intervening decade, covering the socio-economic and political evolutions that have happened, the subsequent effects on population health and the innovative […]

Listen now

Evolution of User Experience for life sciences

Since 2017 we have seen the slow and steady adoption of User Experience (UX) within the life sciences. User Experience is an evidence-based design process that centres on the behaviours and needs of users. The clear benefits of UX offered in the retail and consumer sectors have been slow to percolate to other more complex […]

Listen now

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic

Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this prevalence is allowed to continue the economic and clinical burden will reach a staggering level. Non-alcoholic fatty liver disease (NAFLD) consists of a complex combination of liver maladies, ranging from benign […]

Listen now

Reducing the PAINS in High Throughput Screening: Assay design as a tool for maximising efficiency

This article will describe, with examples, how understanding the likely mechanisms of false positives in advance of screening informs the design of the hit triage, thus increasing the likelihood of discovering optimisable chemical matter and avoiding costly wasting of resource. We describe the use of a bespoke ‘Robustness Set’ of nuisance compounds and how it […]

Listen now

The COVID-19 Race: how mouse models will help researchers cross the finish line

The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission spread and relatively high mortality rates, researchers are under pressure to understand the disease’s pathogenesis, develop and test investigational therapeutics and explore […]

Listen now

Cryo-EM accelerates drug discovery by delivering previously intractable structural insights

Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design. As targets become more challenging, solving structures of drug target molecules or biologics becomes increasingly difficult. Cryo-EM empowers drug discovery teams to take advantage of rational drug design for many more major drug target classes, […]

Listen now

Optimising Phenotypic Screening – Single-cell analysis versus 3D multicell analysis

In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is based on the use of cellular assays and here we debate the advantages and disadvantages of single-cell versus 3D multi-cell analyses. The phenotypic […]

Listen now